Morgan Stanley raised the firm’s price target on CME Group (CME) to $362 from $340 and keeps an Overweight rating on the shares. Better Q1 earnings for brokers and exchanges should modestly beat consensus, but the firm sees modest forward estimate risk and notes in a preview for the group that its forecasts for the group are now 4%-5% below consensus in 2026-27 on average.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target raised to $340 from $328 at TD Cowen
- CME Group resumed with a Market Perform at Keefe Bruyette
- CME Group reports Q1 international ADV 11.4M contracts, up 30%
- CME Group price target raised to $344 from $312 at Barclays
- Crypto Currents: Corporate bitcoin buying outpaces new supply by 62%